Strategic Lab Partnerships Karius' collaboration with Mayo Clinic Laboratories demonstrates the company's ability to integrate its metagenomic infectious disease tests into a major lab ecosystem, enabling streamlined sample submission and reporting within 24 hours. This model can be replicated with other large health systems and IDNs to accelerate deployment of Karius Spectrum and Karius Focus BAL tests across multi-site networks.

Broad Diagnostic Advantage Karius offers broad pathogen detection through clinical metagenomics, supporting rapid, accurate diagnoses and enabling antimicrobial stewardship. This positions the company well for hospitals with high antimicrobial resistance burdens and complex infectious disease cases, with potential to reduce empirical therapy and shorten hospital stays.

Growth Funding Momentum With a $100M Series C in 2024 and recent board enrichments, Karius has capital to scale sales, expand deployments, and invest in enterprise contracts and channel partnerships, supporting long sales cycles with large health systems and academic medical centers.

Credible Academic Partnerships Notable leadership appointments, including Norman Sharpless and Elizabeth O’Farrell, bolster credibility when engaging academic medical centers, cancer institutes, and translational research programs, framing Karius as a trusted partner for clinical adoption studies, reimbursement discussions, and multi-site deployments.

Turnkey Operational Capability The Mayo integration highlights strong logistics and rapid result delivery, addressing hospital needs for streamlined sample flow, LIS/LIMS and EHR integration, and scalable onboarding. Position Karius as a turnkey solution for health systems seeking faster diagnostics and predictable, scalable data sharing.